FETZIMA DIN 02440997
Status: Marketed
Holder: ABBVIE CORPORATION
Available to quote
Health Canada record
| Active ingredient(s) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 80 MG |
|---|---|
| Dosage form | Capsule (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AX28 LEVOMILNACIPRAN |
| Original market date | 22-Apr-2016 |
| Current status date | 10-Oct-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02564831 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 20 MG | Approved |
| 02564858 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 40 MG | Approved |
| 02564866 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 80 MG | Approved |
| 02564874 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 120 MG | Approved |
| 02440989 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 40 MG | Marketed |
| 02441004 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 120 MG | Marketed |
| 02440970 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28846 | 2022-08-29 | New Drug Submission (NDS) | Administrative: Merger/Buy-out |
| 18566 | 2016-10-13 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 16888 | 2015-05-08 | New Drug Submission (NDS) |